Amgen shares are trading higher after the company and AstraZeneca reported Phase 3 data showing TEZSPIRE met co-primary and key secondary endpoints in eosinophilic esophagitis.
Amgen shares are trading higher after the company and AstraZeneca reported Phase 3 data showing TEZSPIRE met co-primary and key secondary endpoints in eosinophilic esophagitis.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed